GlassScriptPhysician profile
Molly Gibbs
NPI 1942880331
$4,103.93
in general payments reported to CMS, 2019-2025
31 companies · $2,021 in 2025
The $2,021 reported for 2025 was more than what 95% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $387 · 2024: $1,696 · 2025: $2,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,822 · Education: $282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,821.95 |
| Education | $281.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $719.26 | 2023-2025 | Darzalex, Tecvayli, Talvey |
| Daiichi Sankyo INC. | $406.15 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Incyte Corporation | $298.64 | 2023-2025 | Monjuvi, Jakafi, Zynyz |
| E.R. Squibb & Sons, L.L.C. | $210.74 | 2023-2025 | Opdivo, Opdualag, Eliquis |
| Abbvie INC. | $204.39 | 2024-2025 | |
| Sobi, INC | $193.56 | 2024-2025 | |
| Teleflex LLC | $176.87 | 2024 | Arrow |
| Exelixis INC. | $176.81 | 2024-2025 | Cabometyx |
| Beone Medicines USA, INC. | $149.37 | 2025 | Brukinsa |
| Merck Sharp & Dohme LLC | $142.68 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Syndax Pharmaceuticals, INC. | $139.99 | 2025 | Revuforj |
| Gilead Sciences, INC. | $136.50 | 2024 | Trodelvy |
| Rigel Pharmaceuticals, INC. | $126.50 | 2024 | Tavalisse, Rezlidhia |
| Genzyme Corporation | $123.92 | 2025 | |
| Geron Corporation | $115.70 | 2025 | Rytelo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $89.72 | 2023-2025 | Tecentriq |
| Alexion Pharmaceuticals, INC. | $88.17 | 2024-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $73.99 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $73.38 | 2024 | Fruzaqla |
| Lilly USA, LLC | $59.75 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Celgene Corporation | $57.58 | 2024-2025 | Reblozyl |
| Pharmacosmos Therapeutics INC. | $51.38 | 2025 | Monoferric |
| Glaxosmithkline, LLC. | $48.68 | 2024-2025 | Jemperli, Zejula, Ojjaara |
| Stemline Therapeutics INC. | $41.07 | 2024 | Orserdu |
| Genmab U.S., INC. | $39.77 | 2024-2025 | Epkinly |
| Eisai INC. | $32.10 | 2024 | |
| Astellas Pharma US INC | $31.49 | 2025 | Cresemba |
| Coherus Oncology, INC. | $29.83 | 2024 | |
| Jazz Pharmaceuticals INC. | $28.69 | 2024 | |
| Cycle Pharmaceuticals INC | $19.21 | 2025 | Phyrago |
| Adc Therapeutics America, INC. | $18.04 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Gibbs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.